NR3C1 and Cushing syndrome due to macronodular adrenal hyperplasia: Mifepristone, a glucocorticoid receptor (GR) antagonist, is indicated for the treatment of refractory Cushing’s syndrome with concurrent hypertension, where it improves both BP and glycemic control.